Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC BNO 1095 in cyclic mastodynia and premenstrual syndrome
2012-005042-37Phase 3Terminated
- Sponsor
- Bionorica
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in mastalgia and premenstrual syndrome (PMS) comparing VAC BNO 1095 with Placebo (2 arms). Primary endpoint: Maximum severity of cyclic breast pain in late luteal phase of 3rd treatment cycle. Started Feb 2013; status: terminated.
02
Drugs
vitex agnus-castus fruit extract
03
Conditions
mastalgiapremenstrual syndrome (PMS)
Beyond the preview
Go deeper on 2012-005042-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005042-37.